The present invention provides a compound, a salt thereof, or a prodrug thereof as a compound effective for preventing and/or treating fibrosis, the compound being represented by formula (1) ##STR00001##
(wherein A is an optionally substituted benzene ring; B is optionally substituted aryl or optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; of Y is a single or double bond when Y is a carbon atom, or of Y is a single bond when Y is a nitrogen atom; each R.sup.1 independently represents lower alkyl, or two R.sup.1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R.sup.1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R.sup.1).sub.p is oxo).

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): ##STR00001##
including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, L, W.sup.1, W.sup.2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

A BRD9 protein degrading compound of structure ##STR00001##
or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.

Ionic cyclic nitroxyl radical oligomers, methods of making the ionic cyclic nitroxyl radical oligomers, and electrochemical cells, such as aqueous organic redox flow batteries (AORFBs) that use the ionic nitroxyl radical oligomers as catholytes are provided. The oligomers are larger than individual cyclic nitroxyl radical molecules, but maintain a high density nitroxyl radical groups within the molecule. As a result, when the oligomers are used as catholytes in an AORFB, they are able to reduce catholyte permeation through the ion-conducting membrane, while providing a high volumetric capacity and cycling stability.

Provided herein are compounds of Formulae (RL), (I), (II), (HI), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

##STR00001##

Provided herein are compounds of Formulae (RL), (I), (II), (HI), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

##STR00001##

Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds. ##STR00001##

Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds. ##STR00001##